Skip Nav Destination
1-9 of 9
Marta ESCRIBANO, Laura MOLERO, Antonio LÓPEZ-FARRÉ, Cynthia ABARRATEGUI, Carolina CARRASCO, Antonio GARCÍA-MENDEZ, Félix MANZARBEITIA, María Jesús MARTÍN, Marian VÁZQUEZ, Paloma SÁNCHEZ-FAYOS, Luis RICO, Juan Carlos PORRES CUBERO
Clin Sci (Lond) (2004) 106 (1): 83–91.
Published: 01 January 2004
... of colon tumour-associated morphological modifications in azoxymethane-treated rats. We studied further whether aspirin treatment changed these parameters. An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found. Aspirin...
Nicolas A. F. Chronos, Darren J. Wilson, Sarah L. Janes, Ronald A. Hutton, Nigel P. Buller, Alison H. Goodall
Clin Sci (Lond) (1994) 87 (5): 575–580.
Published: 01 November 1994
...Nicolas A. F. Chronos; Darren J. Wilson; Sarah L. Janes; Ronald A. Hutton; Nigel P. Buller; Alison H. Goodall 1. Aspirin inhibits the conversion of arachidonic acid to thromboxane A 2 which reinforces the effects of weak agonists such as ADP in platelets. 2. In this study the effect of aspirin (300...
Clin Sci (Lond) (1993) 84 (4): 427–433.
Published: 01 April 1993
... oral administration of the irreversible inhibitor of prostaglandin production, acetylsalicylic acid (aspirin). 3. At a low dose (5 pmol/min), endothelin-1 alone caused slowly developing and long-lasting venoconstriction (maximal constriction: 66 ± 4%). Although glyceryl trinitrate partially prevented...
Clin Sci (Lond) (1991) 81 (s25): 565–573.
Published: 01 October 1991
...C. J. Hawkey; A. B. Hawthorne; N. Hudson; A. T. Cole; Y. R. Mahida; T. K. Daneshmend 1. An increasing body of data suggests that the anti-haemostatic as well as the ulcerogenic actions of aspirin and other non-steroidal anti-inflammatory drugs may be operative when patients present...
Clin Sci (Lond) (1989) 77 (1): 99–103.
Published: 01 July 1989
...R. K. McCulloch; J. Summers; R. Vandongen; I. L. Rouse 1. At present it is unclear whether platelet-activating-factor (PAF)-induced aggregation is mediated by thromboxane. To obtain further information about this event we have compared the affects of aspirin on platelet aggregation and secretion...
Clin Sci (Lond) (1988) 74 (5): 491–497.
Published: 01 May 1988
...D. Sils; S. E. Rodgers; J. V. Lloyd; K. M. Wilson; D. M. Siebert; F. Bochner 1. The aspirin concentrations previously reported to inhibit platelet aggregation in vitro (40–500 μmol/l) are much greater than those required in vivo in man (5 μmol/l). 2. Human platelet-rich plasma was incubated...
Clin Sci (Lond) (1983) 64 (4): 395–398.
Published: 01 April 1983
... in urine fell to 45% of pretreatment levels in 3 days, but returned to pretreatment values after 7 days. 3. These results suggest that production of prostacyclin in vivo is only partially inhibited by high doses of aspirin and that there are sites of production of prostacyclin which are protected from...
Clin Sci Mol Med (1977) 52 (6): 615–620.
Published: 01 June 1977
... topically before and after systemic administration of aspirin. Trafuril alone caused a sustained inflammatory response within minutes of application, which was reduced by prior administration of aspirin (a known prostaglandin synthetase inhibitor). 4. Exudate from inflamed skin showed increased...
Clin Sci (1972) 42 (3): 383–393.
Published: 01 March 1972
.... The percentage uptake of technetium over the proximal and distal diarthrodial joints was significantly decreased in patients with rheumatoid arthritis by the oral administration of aspirin (4 g/day for 7 days) and it is proposed that this method may be of value in the routine assessment of anti-inflammatory drug...